TNF-alpha/TNFSF2 Protein, Human (HEK293, His)

TNF-α/TNFSF2 protein is a macrophage-secreted cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR, inducing tumor cell death and acting as a pyrogen. It is associated with cachexia and stimulates cell proliferation and differentiation. TNF-alpha/TNFSF2 Protein, Human (HEK293, His) is the recombinant human-derived TNF-alpha/TNFSF2 protein, expressed by HEK293 , with C-His labeled tag.

The TNF-alpha/TNFSF2 Protein, a cytokine, binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR, primarily secreted by macrophages with the capability to induce cell death in specific tumor cell lines. Acting as a potent pyrogen, it causes fever through direct action or by stimulating interleukin-1 secretion and is implicated in the induction of cachexia. Furthermore, under specific conditions, TNF-alpha can stimulate cell proliferation and induce cell differentiation. Notably, in individuals with rheumatoid arthritis, it impairs regulatory T-cells (Treg) function via FOXP3 dephosphorylation, up-regulating the expression of protein phosphatase 1 (PP1) that dephosphorylates the key 'Ser-418' residue of FOXP3, rendering Treg cells functionally defective. Additionally, TNF-alpha is a key mediator of cell death in the anticancer action of BCG-stimulated neutrophils in combination with DIABLO/SMAC mimetic in the RT4v6 bladder cancer cell line. It induces insulin resistance in adipocytes by inhibiting insulin-induced IRS1 tyrosine phosphorylation and glucose uptake, leading to GKAP42 protein degradation and TNF-induced insulin resistance. Furthermore, it plays a role in angiogenesis by synergistically inducing VEGF production with IL1B and IL6, and it promotes osteoclastogenesis, contributing to bone resorption. Lastly, the TNF intracellular domain (ICD) form induces IL12 production in dendritic cells, highlighting its diverse impact across various physiological processes.

Measured in a cytotoxicity assay using L-929 mouse fibroblast cells in the presence of the metabolic inhibitor actinomycin D. The ED₅₀ for this effect is 8.203 pg/mL, corresponding to a specific activity is 1.22×10⁸ units/mg.

• 
  Measured in a cytotoxicity assay using L‑929 mouse fibroblast cells in the presence of the metabolic inhibitor actinomycin D. The ED₅₀ for this effect is 8.203 pg/mL, corresponding to a specific activity is 1.22×10⁸ units/mg.
• 
  TNF-alpha/TNFSF2 Protein, Human (HEK293, His) captured on CM5 Chip can bind Adalimumab (HY-P9908) with an affinity constant of 9.96E-10 M as determined in SPR assay (Biacore 8K).

Human

HEK293

C-6*His

P01375 (V77-L233)

7124

Full Length of TNF soluble form

VRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVELRDNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRETPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL

Approximately 17 kDa, based on SDS-PAGE under reducing conditions, due to the glycosylation.

• 
  ≥ 95%, as determined by reducing SDS-PAGE.

Lyophilized powder.

Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.